UCB advances its digital antibody engineering program with new Cradle collaboration

<p>Collaboration adds Cradle's end-to-end platform to UCB's computational capabilities, supporting faster discovery of complex therapies for severe diseases BRUSSELS and AMSTERDAM, Nov. 4, 2026 /PRNewswire/ -- UCB, a global biopharmaceutical company, and Cradle, which builds a leading...</p>